secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0001641172-25-015172
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma reports positive bioequivalence study for undisclosed anticoagulant generic; brand sales $27B
--------------------------------------------------------------------------------

- Positive pivotal bioequivalence results for an undisclosed generic anticoagulant; product is bioequivalent to brand.
- Branded product sales $27B (12 months ending April 2025); no generic marketed; unexpired Orange Book patent exists.
- Elite will compile data to file ANDA with FDA; commercialization conditional on FDA approval and patent resolution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000164117225015172/0001641172-25-015172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000164117225015172/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer